Date Added: 27/06/2017

Date Updated: 27/06/2017

A transdermal glucagon patch for severe hypoglycemia

Specialties: Endocrine, nutritional and metabolic

Technology Type: Devices - Drugs

Stage of development: Experimental - pilot or phase II

Stage of EAA: Assessment Complete

Description, patients and keywords:

The ZP-Glucagon patch uses novel microneedle technology to deliver glucagon through the skin to people who are experiencing severe hypoglycemia (very low blood sugar).

There is very limited evidence, from one small study, comparing the ZP-Glucagon patch with glucagon injected intramuscularly.

The evidence suggests that the correction of blood sugar levels is comparable between the ZP-Glucagon patch and the glucagon injected intramuscularly when tested in a controlled setting.

The ZP-Glucagon patch is not yet commercially available and the anticipated cost is unknown.

In an emergency situation, the ZP-Glucagon patch may be a more user-friendly option than injecting glucagon.


Keywords: Diabetes mellitus, Type 1 diabetes, glucagon, transdermal drug delivery, hypoglycemia